Trial · NCT00586898
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
NCT00586898, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-03-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle. Trials, record NCT00586898. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00586898
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
- NCT number
- NCT00586898
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 36 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Prostate, Cancer, Hormonal Cycling
- Interventions
- GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
- First posted
- 2008-01-07
- Last updated
- 2016-03-25
- Results first posted
- 2016-03-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response | 6 months | Complete Response: Normalization of the PSA (\< or = to 4.0 for patients with castrate metastatic disease, or \< 0.5 for patients with a rising PSA) that is maintained on 3 successive evaluations a minimum of 2 weeks apart. Partial Response: Decrease in PSA value by \> or = to 50% from baseline value (without normalization) for 3 successive evaluations a minimum of 2 weeks apart. Stabilization: Patients who do not meet the criteria for PR or PROG for at least 90 days will be considered stable. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response | 6 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response | All Participants | Complete Response (CR) | 22 | participants | |
| Response | All Participants | Partial Response (PR) | 4 | participants | |
| Response | All Participants | Stable Disease (SD) | 3 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Participants | 36 | |
| Overall Study | COMPLETED | All Participants | 29 | |
| Overall Study | NOT COMPLETED | All Participants | 7 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | All Participants | 6 | 36 | 6 |
| other | Hot Flashes | General disorders | All Participants | 7 | 36 | 7 |
| other | Hyperglycemia | Metabolism and nutrition disorders | All Participants | 8 | 36 | 8 |
| other | Hyperkalemia | Metabolism and nutrition disorders | All Participants | 5 | 36 | 5 |
| other | Hypoglycemia | Metabolism and nutrition disorders | All Participants | 2 | 36 | 2 |
| other | SGPT (ALT) | Metabolism and nutrition disorders | All Participants | 3 | 36 | 3 |
| serious | Pneumonitis | Respiratory, thoracic and mediastinal disorders | All Participants | 1 | 36 | 1 |
| serious | Cardiovascular, other | Cardiac disorders | All Participants | 1 | 36 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Participants | ||
| Total, other adverse events | All Participants | 20 | 36 |
| Total, serious adverse events | All Participants | 2 | 36 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00586898
GET https://conductscience.org/api/trials/v1/NCT00586898/registered